Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 6—June 2010
Research

Clonal Expansion of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, Japan

Yoshiro MuraseComments to Author , Shinji Maeda, Hiroyuki Yamada, Akihiro Ohkado, Kinuyo Chikamatsu, Kazue Mizuno, Seiya Kato, and Satoshi Mitarai
Author affiliations: The Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association, Tokyo, Japan

Main Article

Table 1

Comparison of characteristics between TB patients with XDR TB and non-XDR MDR TB from the most recent (2002) nationwide drug susceptibility survey, Japan*

Characteristic No. (%) cases
Odds ratio (95% confidence interval)
XDR, 
n = 17 Non–XDR MDR, n = 38 MDR/XDR, n = 55 Drug susceptible, n = 2,782 MDR/XDR vs. drug susceptible XDR vs. non–XDR MDR
Age, y
0–20 0 1 (3) 1 (2) 51 (2) 2.57 (–)
21–40 6 (35) 14 (37) 20 (36) 460 (17) 5.69 (2.63–12.45) 0.51 (0.12–2.18)
41–60 10 (59) 12 (32) 22 (40) 701 (25) 4.11 (1.93–8.85) 1
>61
1 (6)
11 (29)
12 (22)
1,570 (56)

1
0.11 (0.00–1.11)
Sex
M 9 (53) 30 (79) 39 (71) 1,973 (71) 1 1
F
8 (47)
8 (21)
16 (29)
809 (29)

1.00 (0.53–1.86)
3.33 (0.83–13.77)
Nationality
Japanese 16 (94) 31 (82) 47 (85) 2,710 (97) 1 1
Foreigner
1 (6)
7 (18)
8 (15)
72 (3)

6.41 (2.69–14.72)
0.28 (0.01–2.64)
Treatment history
New 8 (47) 17 (45) 25 (45) 2,498 (90) 1 1
Previous
9 (53)
21 (55)
30 (55)
284 (10)

10.55 (5.93–18.83)
0.91 (0.25–3.33)
Site of TB
Pulmonary 17 (100) 38 (100) 55 (100) 2,687 (97)
Extrapulmonary
0
0
0
95 (3)



Chest radiograph finding
Noncavitary 5 (29) 8 (21) 13 (24) 1,394 (50) 1 1
Cavitary
12 (71)
30 (79)
42 (76)
1,388 (50)

3.24 (1.68–6.38)
0.64 (0.15–2.84)
Sputum smear test result
Negative 3 (18) 6 (16) 9 (16) 838 (30) 1 1
Positive
14 (82)
32 (84)
46 (84)
1,944 (70)

2.20 (1.03–4.85)
0.88 (0.16–5.23)
Complication
None 6 (35) 21 (55) 27 (49) 1,344 (48) 1
Diabetes mellitus 4 (24) 7 (18) 11 (20) 438 (16) 1.25 (0.58–2.65) 2.00 (0.34–11.88)
Malignancy 3 (18) 2 (5) 5 (9) 180 (6) 1.38 (0.46–3.83) 5.25 (0.52–61.86)

*TB, tuberculosis; XDR, extensively drug-resistant; MDR, multidrug-resistant; MDR/XDR, MDR TB and XDR TB; –, not available. Boldface indicates significance.

Main Article

Page created: February 10, 2011
Page updated: February 10, 2011
Page reviewed: February 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external